OBJECTIVE: In rats transgenic for human HLA-B27 and β(2) -microglobulin (B27-transgenic rats), colitis and peripheral inflammation develop spontaneously. Therefore, B27-transgenic rats provide a model of spondylarthritis. Because inflammation in these rats requires CD4+ T lymphocytes and involves intestinal pathology, we hypothesized that dendritic cells (DCs) that migrate from the intestine and control CD4+ T cell differentiation would be aberrant in B27-transgenic rats. METHODS: Migrating intestinal lymph DCs were collected via thoracic duct cannulation from B27-transgenic and control (HLA-B7-transgenic or nontransgenic) rats. The phenotypes of these DCs and of mesenteric lymph node DCs were assessed by flow cytometry. The ability of DCs to differentiate from bone marrow precursors in vitro was also assessed. RESULTS: Lymph DCs showed increased activation and, strikingly, lacked the specific DC population that is important for maintaining tolerance to self-antigens. This population of DCs was also depleted from the mesenteric lymph nodes of B27-transgenic rats. Furthermore, in vitro culture of DCs from bone marrow precursors revealed a defect in the ability of B27-transgenic rats to produce DCs of the migratory phenotype, although the DCs that were generated induced enhanced interleukin-17 (IL-17) production from naive CD4+ T cells. CONCLUSION: We describe 2 different mechanisms by which HLA-B27 may contribute to inflammatory disease: increased apoptotic death of B27-transgenic DCs that normally function to maintain immunologic tolerance and enhanced IL-17 production from CD4+ T cells stimulated by the surviving B27-transgenic DCs.
OBJECTIVE: In rats transgenic for human HLA-B27 and β(2) -microglobulin (B27-transgenic rats), colitis and peripheral inflammation develop spontaneously. Therefore, B27-transgenic rats provide a model of spondylarthritis. Because inflammation in these rats requires CD4+ T lymphocytes and involves intestinal pathology, we hypothesized that dendritic cells (DCs) that migrate from the intestine and control CD4+ T cell differentiation would be aberrant in B27-transgenic rats. METHODS: Migrating intestinal lymph DCs were collected via thoracic duct cannulation from B27-transgenic and control (HLA-B7-transgenic or nontransgenic) rats. The phenotypes of these DCs and of mesenteric lymph node DCs were assessed by flow cytometry. The ability of DCs to differentiate from bone marrow precursors in vitro was also assessed. RESULTS: Lymph DCs showed increased activation and, strikingly, lacked the specific DC population that is important for maintaining tolerance to self-antigens. This population of DCs was also depleted from the mesenteric lymph nodes of B27-transgenic rats. Furthermore, in vitro culture of DCs from bone marrow precursors revealed a defect in the ability of B27-transgenic rats to produce DCs of the migratory phenotype, although the DCs that were generated induced enhanced interleukin-17 (IL-17) production from naive CD4+ T cells. CONCLUSION: We describe 2 different mechanisms by which HLA-B27 may contribute to inflammatory disease: increased apoptotic death of B27-transgenic DCs that normally function to maintain immunologic tolerance and enhanced IL-17 production from CD4+ T cells stimulated by the surviving B27-transgenic DCs.
Authors: Jane C Goodall; Changxin Wu; Yongsheng Zhang; Louise McNeill; Lou Ellis; Vladimir Saudek; J S Hill Gaston Journal: Proc Natl Acad Sci U S A Date: 2010-09-27 Impact factor: 11.205
Authors: Shalin H Naik; Anna I Proietto; Nicholas S Wilson; Aleksandar Dakic; Petra Schnorrer; Martina Fuchsberger; Mireille H Lahoud; Meredith O'Keeffe; Qi-xiang Shao; Wei-feng Chen; José A Villadangos; Ken Shortman; Li Wu Journal: J Immunol Date: 2005-06-01 Impact factor: 5.422
Authors: Brian T Edelson; Wumesh KC; Richard Juang; Masako Kohyama; Loralyn A Benoit; Paul A Klekotka; Clara Moon; Jörn C Albring; Wataru Ise; Drew G Michael; Deepta Bhattacharya; Thaddeus S Stappenbeck; Michael J Holtzman; Sun-Sang J Sung; Theresa L Murphy; Kai Hildner; Kenneth M Murphy Journal: J Exp Med Date: 2010-03-29 Impact factor: 14.307
Authors: Alfonso MartIn-Fontecha; Silvia Sebastiani; Uta E Höpken; Mariagrazia Uguccioni; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto Journal: J Exp Med Date: 2003-08-18 Impact factor: 14.307
Authors: Elin Jaensson; Heli Uronen-Hansson; Oliver Pabst; Bertus Eksteen; Jiong Tian; Janine L Coombes; Pia-Lena Berg; Thomas Davidsson; Fiona Powrie; Bengt Johansson-Lindbom; William W Agace Journal: J Exp Med Date: 2008-08-18 Impact factor: 14.307
Authors: Ingrid Fert; Nicolas Cagnard; Simon Glatigny; Franck Letourneur; Sébastien Jacques; Judith A Smith; Robert A Colbert; Joel D Taurog; Gilles Chiocchia; Luiza M Araujo; Maxime Breban Journal: Arthritis Rheumatol Date: 2014-04 Impact factor: 10.995
Authors: Mark J Asquith; Patrick Stauffer; Sean Davin; Claire Mitchell; Phoebe Lin; James T Rosenbaum Journal: Arthritis Rheumatol Date: 2016-09 Impact factor: 10.995